MedPath

Palbociclib: A New Option for Front-Line Treatment ...

Breast cancer mortality in American women is decreasing due to early detection and treatment advances. Palbociclib, combined with letrozole, is FDA-approved for ER+, HER2– metastatic breast cancer, showing improved progression-free survival. Ongoing studies aim to confirm its efficacy and explore its use in other cancers and treatment settings.

Related Clinical Trials

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Reference News

pmc.ncbi.nlm.nih.gov
Palbociclib: A New Option for Front-Line Treatment ...

Breast cancer mortality in American women is decreasing due to early detection and treatment advances. Palbociclib, combined with letrozole, is FDA-approved for ER+, HER2– metastatic breast cancer, showing improved progression-free survival. Ongoing studies aim to confirm its efficacy and explore its use in other cancers and treatment settings.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy